JX09 vs Lorundrostat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline

JX09

Developed by Ji Xing Pharmaceuticals (CORXEL)

Phase 1 in Hypertensionsmall molecule
Partial signal

NCT06183671 · Phase 1 · completed

This is a randomized, blinded, placebo-controlled phase 1 study in 92 healthy volunteers testing single and multiple ascending doses of JX09, with safety and tolerability as the primary focus rather than a disease efficacy measure. Results have not been posted.

No aligned efficacy figure on record for this race.

Lorundrostat

Developed by Mineralys Therapeutics and partners

Phase 3 in Hypertensionsmall molecule
Reliable signal

NCT05769608 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial in 285 patients with uncontrolled hypertension that measured 24-hour ambulatory systolic blood pressure, the standard efficacy measure for this disease. The 50 mg lorundrostat dose lowered ambulatory blood pressure significantly more than placebo at week 12.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) (met)

Result source: NCT06153693

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJX09Lorundrostat
Seated SBP, change—Not reported—Not posted · NCT06153693
24-hour ambulatory SBP, change—Not reported—Not posted · NCT06153693
Seated DBP, change—Not reported—Not posted · NCT06153693

Seated SBP, change

JX09
—Not reported
Lorundrostat
—Not posted · NCT06153693

24-hour ambulatory SBP, change

JX09
—Not reported
Lorundrostat
—Not posted · NCT06153693

Seated DBP, change

JX09
—Not reported
Lorundrostat
—Not posted · NCT06153693
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JX09: no structured comparison results are available for Hypertension.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. JX09: 0 of 4 rows · Lorundrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorundrostat
Dropout rate
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Discontinued due to AEs
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Serious AEs
3.4%
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Most frequent reported AEs
hyperkalaemia 15.5% (placebo 3.5%)
glomerular filtration rate decreased 10.3% (placebo 3.5%)
hyponatraemia 5.2% (placebo 5.3%)
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorundrostat

AOBP SBP -9.253 vs -1.755 placebo mmHg @ 4wk
absolute change · mmHg
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Ambulatory SBP -7.9 mmHg @ 12wklorundrostat 50 mg arm
absolute change · mmHg
No placebo or comparator arm
NCT05769608 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JX09's landscape · Lorundrostat's landscape